GAGuilherme Bastos Alves

Guilherme Bastos Alves

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guilherme Bastos Alves has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Computational and Experimental Evaluation of Antibacterial, Antidiabetic, Antioxidant, and Anti-Inflammatory Activities of Piperazine Derivative

    by Sonam Shakya, Gabriel Morais, Guilherme Alves, F.M. Mashood Ahamed, Mushira Banu Ahmed Meeran, Hosen, Prithiyunan Mani, Ishat M. Khan, Caio Sena, Davi Vieira, et al.

    This study investigated the synthesis, characterization and pharmacological evaluation of a novel piperazine derivative, 1-[(2-Nitro-phenyl)-piperazin-1-yl-methyl]-3-phenyl-urea (SC). Its antibacterial, antifungal, anti-inflammatory, antioxidant and antidiabetic activities were evaluated using both in silico and in vitro methods. SC was synthesized from N-phenylurea, piperazine and 2-nitrobenzaldehyde and was subsequently characterized by FTIR and 1H-NMR spectroscopy. Antibacterial activity was tested against MRSA and Escherichia coli, showing significant inhibition, while antifungal activity against Candida albicans and Aspergillus niger demonstrated remarkable results. The anti-inflammatory properties were evaluated with the Bovine Serum Albumin (BSA) assay, revealing a strong inhibitory effect. Antioxidant activity, measured by the DPPH assay, demonstrated substantial free radical scavenging activity. Furthermore, α-amylase inhibition assays indicated potential antidiabetic properties. Molecular docking and dynamics simulations confirmed a strong binding affinity of SC with the target proteins. Pharmacokinetic predictions, which evaluated the ADMET profile of SC compared to standards, revealed a reasonable oral absorption and safety profile. These findings position SC as a promising candidate for further development as a therapeutic agent addressing multiple healthcare challenges.

  • Open Access

    Assessment of Annona muricata Phytochemicals as 17β‐HSD1 Inhibitors through Molecular Docking, Dynamics Simulation, DFT, and ADMET Analyses

    by Emad Rashad Sindi, Jannatul Islam Polash, Guilherme Bastos Alves, Imren Bayil, Samson Olusegun Afolabi, Hanan M. Alharbi, Alaa A. Khojah, Jonas Ivan Nobre Oliveira, Aamal A. Al‐Mutairi, Magdi E. A. Zaki

    Breast cancer remains a leading cause of female mortality, largely sustained by local oestrogen production. The enzyme 17β‐hydroxysteroid dehydrogenase type 1 (17β‐HSD1) is an enzyme involved in the oestrogen biosynthesis pathway, particularly in the conversion of estrone to estradiol, and is overexpressed in conditions such as breast cancer. Therefore, it is considered a relevant target for drug development. We evaluated phytocompounds from Annona muricata as prospective 17β‐HSD1 inhibitors through an integrated in silico workflow. Twelve reported constituents (myristic acid, myrcene, palmitic acid, hexanoic acid, pentadecane, methyl 3‐phenylpropionate, butyric acid, linalool, reticuline, phytol, camphene and calamenene) were geometry‐optimised by density‐functional theory, docked against 17β‐HSD1 (PDB 3HB5), and screened for drug‐likeness and ADMET liabilities. The top‐ranked complexes—reticuline (ΔG_pred = −8.4 kcal mol −1 ) and calamenene (−7.7 kcal mol −1 )—scored more favourably than the reference epirubicin (−5.7 kcal mol −1 ) and were subjected to 100 ns molecular‐dynamics simulations. Both ligands remained stably anchored within the catalytic pocket, with root mean square deviation (RMSD) fluctuations below 2.0 Å, yet MM‐PBSA binding free energies (reticuline −27 kJ mol −1 ; calamenene −9 kJ mol −1 ) did not surpass the reference. ADMET profiling predicted acceptable Caco‐2 permeability (0.92–0.94), and only moderate hERG liability, but also signalled potential DILI and carcinogenicity alerts that warrant caution. Reticuline and calamenene fulfilled all of Lipinski's criteria, with the exception of logP in the case of calamenene. Collectively, these findings nominate reticuline and calamenene as promising lead scaffolds for selective intracellular suppression of oestrogen biosynthesis. Experimental validation (enzyme kinetics, cell‐based assays and pharmacokinetic studies) is warranted to confirm their clinical potential in oestrogen‐dependent breast cancer.


  • Identification of Therapeutic Compounds Targeting Phosphatidylinositol 3-Kinase (PI3K) Through Molecular Docking, Dynamics Simulation, and DFT Calculations

    by Jehad Zuhair Tayyeb, Imren Bayıl, Taha Alqahtani, Gabriel Vinícius Rolim Silva, Guilherme Bastos Alves, Al-Anood M. Al-Dies, Abdelkrim Guendouzi, Jonas Ivan Nobre Oliveira, Magdi E.A. Zaki